| Description | IRAK4-IN-20 is a potent and orally active IRAK4 inhibitor (IC50:3.55 nM). IRAK4-IN-20, which has anti-inflammatory, antitumor and anticancer effects, is often used to treat acute respiratory distress syndrome (ARDS). |
| In vitro | IRAK4-IN-20 (Compound BAY-1834845) (500 nM, 20 h) decreases inflammatory cytokines secretion effectively in an in vitro treatment of LPS stimulated human peripheral blood mononuclear cells (PBMC) [1]. |
| In vivo | IRAK4-IN-20 (Compound BAY-1834845) (150 mg/kg; p.o.; once or twice) effectively prevents acute respiratory distress syndrome in mice [1]. Animal Model: Female Balb/c mice (aged 6–7 weeks), LPS-induced ARDS mouse model [1] Dosage: 150 mg/kg Administration: Oral administration, 30 min before LPS modeling or twice 4 h and 12 h after LPS modeling Result: Remarkably decreased inflammatory cells infiltrating lung tissue and neutrophil count in BALF. Effectively reduced the numbers of total T cells, monocyte, and macrophages. Largely preserved the signatures of na ve lymphocytes and stromal cells such as endothelial cells, chondrocytes, and smooth muscle cells. Regulated inflammation and innate immunity genes more efficiently than Dexamethasone. |
| Target activity | IRAK4:3.55 nM |
| Synonyms | BAY-1834845 |
| molecular weight | 450.45 |
| Molecular formula | C22H25F3N4O3 |
| CAS | 1931994-80-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 25 mg/mL (55.5 mM) |
| References | 1. Li Q, Li R, Yin H, et al. Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomed Pharmacother. 2022;153:113459. |